Zepbound or Wegovy? The Honest Side-by-Side Comparison

Zepbound at a glance:

• Drug class: Dual GIP / GLP-1 receptor agonist
• Manufacturer: Eli Lilly
• FDA approved: 2023
• Route: subcutaneous injection (single-dose pen)
• Typical frequency: once weekly
• Half-life: approximately 5 days
• Cash price (US): $1,000-$1,100/month without insurance
• Receptor target: GIP and GLP-1 receptors (dual)

If you're choosing between two specific options, the right framework is rarely "which is better in general" — it's "which is better for me, given my insurance, side-effect tolerance, and dosing preference." We try to make that comparison honest below.

Mechanism

Zepbound: Zepbound is tirzepatide labeled and dosed for weight loss. By activating both GIP and GLP-1 receptors, it produces greater appetite suppression and weight loss than GLP-1 monotherapy in head-to-head trials.

Wegovy: Wegovy is semaglutide labeled and dosed for weight loss. It targets the same GLP-1 receptor pathways as Ozempic but at a higher target dose (2.4 mg weekly) to maximize appetite suppression and weight reduction.

For people new to this comparison, the practical takeaway is that the underlying mechanisms are different enough that response can vary.

Dosing & Administration

Effectiveness

Zepbound: Mean weight loss of 20.9% at the 15 mg dose at 72 weeks in SURMOUNT-1, vs 3.1% on placebo. Improved sleep apnea severity in SURMOUNT-OSA.

Wegovy: Mean weight loss of 14.9% of body weight at 68 weeks in STEP 1 (vs 2.4% on placebo). Cardiovascular benefit demonstrated in SELECT.

In head-to-head comparisons (where they exist), the higher-dose newer agents tend to outperform older ones — sometimes meaningfully. Reference trials: SURMOUNT-1 (Jastreboff 2022, NEJM) — 20 for Zepbound; STEP 1 (Wilding 2021, NEJM) — 14 for Wegovy.

Side Effects

The two compounds have overlapping side-effect profiles. Common to both:

• nausea
• diarrhea
• vomiting
• constipation
• abdominal pain
• injection-site reactions

Important risks worth knowing for both:

• pancreatitis
• gallbladder disease
• thyroid C-cell tumors (boxed warning)
• acute kidney injury

Cost

Zepbound: $1,000-$1,100/month without insurance. Wegovy: $1,300-$1,400/month without insurance.

Insurance coverage and manufacturer programs change the relative cost picture significantly. See our individual cost guides for Zepbound cost and Wegovy cost for the latest numbers.

Which Is Right for You?

The practical decision usually comes down to four factors:

1. What's covered by your insurance? Often the deciding factor
2. What does your prescriber have experience with? Familiarity reduces dosing errors
3. How comfortable are you with injections (or oral dosing if applicable)?
4. What's your tolerance for side effects?

If you and your clinician end up split between Zepbound and Wegovy, either is a defensible choice in most cases.

Switching Between Them

Switching from Zepbound to Wegovy (or the reverse) is usually straightforward but should be done with clinician guidance — particularly to align dose escalation and avoid GI side effects from re-titration.

Bottom Line

Both Zepbound and its alternative are defensible choices. The right pick comes from your specific situation — insurance, prescriber, tolerance — not from the molecule alone.

Frequently Asked Questions

Related Reading

• The Honest Guide to Zepbound: What Patients and Doctors Actually Say
• What Nobody Tells You About Zepbound Side Effects
• Zepbound Outcomes Decoded: Who Responds Best and Why
• Zepbound Cost Explained: Monthly, Yearly, and How to Save
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.
• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.
• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221.

This page is informational only and is not a personalized recommendation. The right choice depends on your individual situation.